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Medical imaging has rapidly increased in numbers and cost. Evaluation of diagnostic methods 
has much focused on accuracy, but less on cost and hazard. Advanced tests for coronary 
artery disease are expensive and carry a risk. In heart transplant (HTx) patients, coronary 
vasculopathy is prevalent, and annual follow-up comprises a coronary angiography.   Less 
costly and low-risk techniques with adequate accuracy are desired.  In this study we tested the 
diagnostic accuracy and cost of three available medical techniques to detect coronary artery 
stenosis (CAD) in HTx patients. 
Methods:  Fifty stable HTx patients aged (mean±SD) 57±8 years were studied during annual 
routine control with dobutamine stress echocardiography (dobECHO), dobutamine 
99m
Tc-
tetrofosmin emission tomography (dobSPET) and exercise ECG (exECG), and compared with 
coronary angiography.  Cost of methods were derived from hospital accountancy data.   
Results: Significant coronary artery stenosis in ≥1 major epicardial vessel was present in 14 
patients (28.0%), but only 16 (32.0%) had complete normal angiograms.  Sensitivity, 
specificity, and accuracy for CAD as compared to angiograms, was for dobECHO: 67%, 91%, 
and 82%; for dobSPET: 71%, 74%, and 73%; and for exECG: 20%, 91%, and 70%, 
respectively. By combining dobECHO with echocardiographic wall motion analysis, the rate 
of false negatives was reduced to 4%. Cost of dobECHO, dobSPET and exECG was 
estimated to 0.58, 1.45, and 0.25 times cost of angiography. DobSPET gives similar radiation 
exposure (7 mSv) as angiography.  
Conclusion: DobECHO and dobSPET are feasible tests in HTx patients.  DobECHO or 
dobSPET alone or combined with echocardiographic resting wall motion analysis, can be 
used with acceptable accuracy for identifying HTx patients in whom routine coronary 
angiography intermittently can be deferred. Of these, dobECHO is the least expensive, and 
carries the least risk to the patient. ExECG has low accuracy and cannot be recommended in 
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Medical imaging has over the last three decades become pivotal in diagnosis, treatment and 
monitoring of a vast range of diseases. The benefit of improved diagnostic precision with 
earlier detection of disease, better planning of medical and surgical treatment has been 
immense for patients. This is the result of major advances in medical technology and 
engineering, combined with new treatment principles for prevalent disease entities as 
ischemic heart disease and cancer. International guidelines for diagnosis, treatment and 
monitoring of patients with established or at risk for heart disease have been produced by the 
international medical professional organizations (1-6). With the intention of benefit for the 
patient, algorithms for clinical decision making in these recommendations, often include a 
frequent use of advanced medical imaging techniques, in particular for patients with 
established heart disease, patients with cancer, with pulmonary disease and patients with 
rheumatologic diseases.   
The increase in medical imaging over the last decades (7) has contributed to the concordant 
significant increase in health costs in the developed countries. For example, the estimated 
annual cost of medical diagnostic imaging in the United States in 2004 was USD 100 billion 
(8), with cardiac imaging as a major contributor with more than 9.3 million myocardial 
nuclear perfusion scans performed in the United States in 2002 (9) and with an increasing 
number of investigations thereafter (10).  
1.1 Radiation exposure 
Ionizing radiation is the basic principle of imaging techniques as X-ray, fluoroscopy,  
angiography, and computerized tomography (CT). Nuclear medical imaging techniques utilize 
isotopes with short half-life which emits radiation to the patient and personnel.  There are, 
however, also natural sources of radiation as cosmic background radiation, inhalation of 
radioactive substances, i.e. radon gas, and ingestion of radioactive substances in food (11). 
The radiation exposure generated by medical imaging has steadily increased over the last 
three decades, and now cumulates to approximate the magnitude of natural source of radiation 
(11). Myocardial nuclear perfusion imaging and coronary angiography accounts for 22% and 
5% of the total effective radiation dose by medical imaging in US, respectively (12). 
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1.2 Choice of imaging modality 
Hitherto, the preferred imaging modality has in principle been the best diagnostic method 
available for the patient. Method quality has traditionally been assessed by testing in the 
clinical situation (13). Any new diagnostic method will in principle be evaluated in terms of 
sensitivity, specificity, and diagnostic accuracy when compared with a “gold standard” 
method. The best diagnostic method regardless of cost and risk is regarded “diagnostic gold 
standard”.  The second level is evaluation of the method’s added value compared to existing 
methods. The third level is assessment of the new method’s ability to predict outcome in 
patients. The fourth level is assessment of the cost of the new method in comparison with the 
other available methods. Unfortunately, many methods are introduced on the basis of results 
for the first or two of these levels only.  
The major increase in total cost of medical imaging worldwide strongly support that choice of 
test also should be based on proven cost-effectiveness. In consequence, the diagnostic yield of 
a method should be balanced against cost and hazard inferred to patients, personnel and 
society (14). 
1.3 Medical hazard 
Any medical imaging method will in principle influence living tissue. The hazard by use of 
the relevant methods can be summarized as in Table I. Acute hazard refers to the risk of 
adverse events during or immediately after a patient exam with the particular method. Chronic 
hazard refers to long term biological effects that may elicit or worsen disease progression.  
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SPET = Single photon emission tomography, CT = Computed tomography, MRI = Magnetic resonance imaging,  
More attention is drawn to the acute hazards of the diagnostic tests, than to their potential 
chronic hazards. Of the acute hazards, the most feared adverse event is a cerebral insult, i.e. 
stroke, acutely inflicted on the patient by an embolus produced by an arterial catheterization. 
Although, many strokes resolves with an acceptable outcome, cerebral insult is a threat to all 
patients scheduled for angiography of the coronary arteries, thoracic aorta, or cervical arteries. 
For coronary angiography, the expected rate of severe complications is 0.5 to 2% (15-17), 
however, the risk rate varies between patient populations, and are higher in women and 
elderly. Moreover, hypertensive atherosclerotic patients with long lasting procedures have 
higher complication rates than young, normotensive patients without vascular disease where 
procedure time usually is short.  
Coronary angiography and coronary CT necessitates the use of radio-opaque contrast medium 
which impairs renal function (18), and may elicit allergic reactions. Renal failure is usually 
reversible, but may be permanent in susceptible patients and require the use of temporary or 
permanent hemodialysis.  
Diagnostic use of ionizing techniques represents a hazard to personnel performing the exams. 
To reduce the radiation exposure on personnel, protective coating and glasses containing lead 
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are obligatory during exam. However, these protective measures cannot eliminate radiation 
exposure to personnel. Therefore, radiation dosimeters are mandatory and should be worn by 
all health workers in environment using ionizing radiation. Dosimeters should be regularly 
monitored by experts on health physics. Standards are established that dictates the maximal 
radiation dosage for personnel.  
1.4 Heart transplant patients 
Heart transplantation is the preferred treatment for end-stage heart disease where all other 
treatment modalities have been exhausted. The number of heart transplantations is limited by 
the availability of donator hearts. Thus, a strict selection of patients has been implemented in 
order to preserve the optimal result for the donated organs. Norway is part of the 
Scandinavian heart transplant network. Available donor organs are exchanged between the 
other countries in this network. Organ transplantation requires an immunological 
compatibility, and there is time limit between organ explant and implant (usually 6 hours) set 
to preserve donor organ function, which both restrict the use of organs from more distant 
locations.  
The annual rate of heart transplantations in Norway varies between 25 and 40, median 
survival time is 12 years (19) (Figure 1), and there are at present approximately 400 patients 
living with heart transplants in Norway today.  
 
Figure 1. Cumulative survival for 522 first-time heart transplant recipients, Rikshospitalet, Norway. Adapted 




1.5 Immunosuppressive treatment 
Immunosuppressive treatment is necessary to avoid host versus graft rejection. 
Immunosuppressive regimens are based on pharmacological calcineurin inhibition by 
cyclosporine or tacrolimus, in addition to prednisolone and mycofenalat or everolimus. 
Immunosuppressive treatment minimizes the risk for transplant rejection, but have adverse 
effects such as impairment of renal function and hypertension (20).  
1.6 Vasculopathy in heart transplant patients 
Heart transplant patients are prone to develop vasculopathy (21), which is a major cause for 
their morbidity and mortality (22). This vasculopathy comprises atherosclerosis with a more 
transplant-specific vasculopathy characterized by increased endothelium thickness, both 
resulting in reduction of vessel lumen (21, 23, 24). Particularly important are vasculopathy in 
the transplant coronary arteries. Since the grafted heart is denervated, heart transplant patients 
do generally not experience typical chest pain (i.e. angina pectoris) during myocardial 
ischemia. More typically, an unspecific reduction of exercise capacity is typical for 
development of significant coronary artery disease in these patients. Thus, to reduce the risk 
of acute myocardial infarction, severe arrhythmias and heart failure after heart transplantation, 
a rigorous follow-up procedure has been implemented at most transplantation centers.  In 
principle, all surviving patients are recommended an annual major follow-up comprising 
clinical exam, blood tests, echocardiography and coronary angiography.  
Coronary angiography is regarded to be an expensive diagnostic method with potential hazard 
for the patient, and will due to the diffuse process of transplant vasculopathy not always be 
able to identify significant narrowing (stenosis) of the coronary arteries (25, 26). Thus, there 
has been a desire to replace it at least intermittently, with less costly methods with less risk, 
and adequate diagnostic accuracy.  
1.7 Methods for detection of myocardial ischemia 
In principle, there are three relevant alternative clinical methods available for identification of 




Exercise electrocardiogram (ExECG) 
ExECG has been established as the first level test for patients suspect of having coronary 
artery disease (27). With ExECG, a 12 channel surface electrocardiogram is recorded from the 
patient at rest and during exercise. Typical voltage-alterations in the ECG pattern, i.e. so 
called STT segment depression, are used to identify ischemia. In populations with moderate 
prevalence of coronary artery disease, exECG have repeatedly proven diagnostic precision 
which is but moderate, with sensitivities 60-80%, specificities 80-90% and diagnostic 
accuracy 70%. 
The test is feasible and safe for most patients (28), but requires that the patients is able to 
perform leg exercise either by ergometer bicycle, treadmill or step case. 
 Perfusion single photon emission tomography (SPET) 
SPET has been widely used and established as the preferred second level method in diagnosis 
of coronary artery disease after exECG. With SPET, a radioactive short-lived isotope 
perfusing the myocardium is injected at rest and during peak exercise. The isotope emits 
photons that are recorded by a gamma camera, and differences in myocardial perfusion 
between rest and exercise can be detected as markers of ischemia (29). SPET is feasible in 
most patients since both medication (adenosine, dipyridamole or dobutamine) and ergometer 
bicycle/treadmill exercise can be employed to induce myocardial ischemia. Diagnostic 
accuracy is regarded better than exECG, in particular is the sensitivity higher, whereas 
specificity is somewhat lower.   
Stress echocardiography 
Stress echocardiography is an alternative to SPET in diagnosis of coronary artery disease 
(30). With stress echocardiography, ultrasound images of the left ventricle are obtained at rest 
and during increasing heart rate. Left ventricular wall motion is visually assessed at baseline 
and during stress, and reduced contractions (wall thickening) indicate ischemia.   Stress 
echocardiography is feasible in most patients since both medication (dobutamine, 
dipyridamole) and ergometer bicycle/treadmill exercise can be employed to induce 
myocardial ischemia. 
It is important to note that these alternative methods are designed to detect myocardial 
ischemia which is the presumed physiological result of significant coronary artery stenosis. A 
stenosis is defined as significant when the vessel diameter is reduced at least 50% as 
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compared to preceding segments. At rest, when little demands are put on the myocardium, 
even significant coronary artery stenosis do normally not elicit myocardial ischemia. 
However, when the patient starts to work and myocardial work and oxygen demands raise, 
ischemia and typical chest pain (angina pectoris) are elicited (31).  
1.8 Other imaging modalities  
Recently, computed tomography (CT) and magnetic resonance imaging (MRI) have been 
used to visualize coronary arterial anatomy (32). The precision of these methods have 
increased rapidly. CT is now used for screening of low-prevalence patients with chest pain to 
identify normal coronaries. If pathology is identified, coronary angiography is still needed.  
MRI has been used in a stress test setting for detection of myocardial ischemia (33). Both 
these techniques are, however, costly. They were not relevant at the time of planning of the 




All heart transplantations and the main medical follow-up of HTx patients in Norway are 
performed at our institution.  In the present study, patients were included after giving written 
informed consent. The study was approved by the Regional Committee for Ethics in 
Medicine.  All patients were required to be clinically and hemodynamical stable without 
evidence for transplant rejection on endomyocardial biopsy.  Patients with coronary 
vasculopathy on angiography were selected into the study by an outside observer in order to 
obtain that at least 20% of the group had CAD.  Observers were blinded for patients’ coronary 
status. The purpose of this semi-selection was to assure that a significant proportion, unknown 
to the other observers, of the study group had significant coronary artery disease. A too low 
prevalence of significant coronary artery disease in the study group would not allow 
evaluation of the accuracy of the diagnostic tests.  
In all, fifty patients were included, and underwent head-to-head comparisons of dobECHO, 
dobSPET, and exECG testing as compared to the gold standard method, coronary 
angiography which was performed less than 4 weeks apart from the noninvasive tests.   
2.1 Cardiac catheterization  
Left heart catheterization with coronary angiography was performed by conventional Judkin´s 
technique and each coronary artery assessed in at least 3 views.  Coronary vasculopathy was 
assessed by an experienced radiologist without knowledge of patient data. A 
hemodynamically significant stenosis was considered present when vessel diameter stenosis 
was ≥50%.  Right heart cardiac catheterization was performed using a standard Swan-Ganz 
balloon catheter technique. 
2.2 Dobutamine stress echocardiography 
A standard stress protocol was used. After resting recordings, dobutamine was infused 
intravenously in 3-minute increments from 5 to 40 µg/kg/min in increments of 3 minutes. 
Conventional ultrasound images of the left ventricle were obtained at baseline, during and at 
peak stress. The test was completed at peak stress which was defined as the occurrence of 
either 1) new or worsened wall motion abnormality; 2) heart rate ≥85% of age determined 
maximum (220 - age in years); 3) severe hypertension with either systolic or diastolic blood 
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pressure above 200 and 110 mmHg, respectively; 4) significant patient discomfort, or 5) peak 
dobutamine dose (40 µg/kg/min).  
Image analysis was performed off-line by comparing wall motion and thickening in 16 left 
ventricular segments at baseline and during test by an experienced observer who was blinded 
for results of the other tests.  A score was assigned to each of 16 left ventricular segments 
excluding the apical cap (34, 35). Ischemia was defined as new or worsening wall motion in 
at least 1 myocardial segment during test. The analysis was repeated by a blinded second 
observer for assessment of inter-observer repeatability.   
2.3 Dobutamine stress SPET (99mTechnetium-tetrofosmin 
myocardial perfusion imaging)  
Baseline perfusion registrations were first obtained. Technetium-tetrofosmin (Myoview
TM 
, 
Amersham, Buckinghamshire, UK) were intravenously administrated to patients with 
bodyweight below 75 kg, else 300 MBq was given. Single photon emission tomography 
(SPET) was performed 1 hour later. Later the same day, patients underwent a dobutamine 
stress test protocol identical with that used for the stress echocardiography. At 1.5 minute at 
peak dobutamine dose, the infusion was briefly terminated and a second dose of 750 MBq 
(<75 kg) or 900 MBq (≥75 kg) was injected intravenously, before the dobutamine infusion 
was resumed for the final minute. Following 30 - 60 minutes after test termination, a second 
SPET was performed. 
Image processing and analysis was performed on the APEX Expert System (Elscint) with the 
CEqual
TM
 software using both automatic and observer determined assessment of myocardial 
perfusion images.  
2.4 Exercise ECG test 
Maximal symptom-limited exercise testing was performed using an electrically braked 
bicycle ergometer. The test protocol was individualized using a starting load of 20-50 W 
increasing by 20 W every second minute until exhaustion. Exercise test was terminated at 
either of: patient exhaustion, typical chest pain, significant ST segment depression (≥ 2 mm 
measured 0.8 s after J-point), significant arrhythmias, or hypotension (drop in systolic blood 
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pressure >20 mmHg).  Myocardial ischemia was defined by typical ST-T segment changes in 
2 or more ECG leads. 
2.5 Cost analysis 
The variable and basic cost for each of the four diagnostic methods was estimated on the basis 
of accountancy data from Oslo University Hospital. For the calculations, the following 
assumptions were made: 1. Personnel cost including overhead was for physician set to 1000 
NOK per hour, and for technician 500 NOK per hour. Personnel attendance in time is derived 
from the average values given by leaders of the respective hospital sections performing these 
methods (personal communication, dr. Knut Endresen, Section of Coronary Intervention, dr. 
Fjeld, Department for Nuclear Medicine, both Oslo University Hospital, Rikshospitalet), and 
own knowledge about exECG and dobECHO resources. Cost of single-use equipment and 
medication was derived from hospital accountancy, housing costs were assumed equal for the 
methods.  The additional cost by a coronary angiography – only based strategy per false 
negative exam by any other method was obtained as cost of coronary angiography minus cost 
of method divided by %false negative exams (36). 
2.6 Statistics 
Results are presented as mean values with standard deviation (SD).  The results of the 
respective noninvasive tests were compared to coronary angiography, with respect to overall 
test positivity for ischemia and for the location of ischemia related to the typical coronary 
vessel distribution. In this comparison, coronary stenosis was defined significant when ≥ 1 
significant stenosis was present in any of the major epicardial vessels (LAD, CX or RCA), or 
in any of their major branches.  Sensitivity, specificity, positive and negative predictive 
values, and diagnostic accuracy of each test were determined by conventional methods (37).  







In all, 18 patients (36.0%) had significant stenosis on ≥ 1 of the three major epicardial vessels, 
23 (46.0%) had diffuse changes in major vessels and 16 (32.0%) in peripheral vessels.  
Sixteen patients (32.0%) had completely normal angiograms. No adverse events occurred.  
Dobutamine stress echocardiography  
Left ventricular resting wall motion abnormalities were present in 37 (74.0%).  Scar formation 
was present in 17 (34.0%) patients, 14 (28.0%) in the LAD region. Reversible ischemia was 
found in 16 patients (32.0%), 10 (20.0%) comprising the LAD region.  Sensitivity, specificity, 
and diagnostic accuracy was 67, 91, and 82%, respectively. Positive and negative predictive 
value was 80 and 83%. No adverse events occurred. The inter-observer agreement for 
interpretation of dobECHO was for reversible ischemia in ≥ 1 segment 74%, and for scar 
tissue 84%. 
Dobutamine SPET test  
Resting perfusion abnormalities were found in anterior wall in 10 patients (20.8%) and in 
inferior wall in 7 (14.6%). Evidence for irreversible injury, i.e. fibrosis, was present in 13 
(27.1%), 9 (18.8%) in the LAD region, 2 (4.2%) in the CX region, and 9 (18.8%) in the RCA 
region, affecting 16±9% of the myocardium. Nineteen (39.6%) had evidence for reversible 
ischemia, and the ischemic region comprised 7±4% of the myocardium.  Sensitivity, 
specificity, and diagnostic accuracy was 71, 74, and 73%, respectively. Positive and negative 
predictive value was 60 and 82%. No adverse events occurred.   
Exercise ECG 
In 8 patients (17.8%) ECG was not interpretable for ischemic changes due to complete right 
bundle branch block in 7 patients and technically inadequate ECG in one. Of the 33 patients 
completing the test, only 4 (12.1%) had ECG changes positive for myocardial ischemia, 
Sensitivity, specificity, and diagnostic accuracy was 20, 91, and 70%, respectively. Positive 





3.1 False negative tests  
There were 6 false negative tetsts (12.0%) in dobECHO, 5 (10,4%) in dobSPET, and 8 
(24,2%) in exECG.  By combining dobECHO and dobSPET with resting echocardiography, 
false negatives were reduced to 2 and 0 patients, respectively.   
3.2 Analysis of cost of the diagnostic tests 
The estimated cost per exam in terms of personnel costs, used of medication and single use 
equipment was for dobECHO, dobSPET, exECG and coronary angiography  NOK 1.961,  
4.867, 829, and 3.356, respectively (Table 2).  
Table 2. Estimated cost of diagnostic tests for myocardial ischemia
 
*Assumptions: See Methods section.   
Cost
(in 1000 NOK)
dobECHO dobSPET exECG Angiography
Time for exam (h) 1 4 0,5 1
Number of physicians (N) 1 1 1 1
Number of technicians (N) 1 2 1 2
Salary phys pr exam 0,921 0,921 0,461 0,921
Salary techn pr exam 0,500 1,200 0,250 1,000
Variable expenses
Medication per exam 0,200 2,100 0,000 0,317
Single use equipment 0,100 0,100 0,050 0,550
Sum variable costs 1,721 4,321 0,761 2,788
Basic expenses
Equipment cost per exm 0,195 0,455 0,034 0,284
Equipment maintenance per exam 0,045 0,091 0,034 0,284
Housing = equal 0 0 0 0
Sum basic cost 0,240 0,545 0,068 0,568
Total costs per exam 1,961 4,867 0,829 3,356
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When using cost of coronary angiography as unity, the cost of the exECG was 0.25, 
dobECHO 0.58 and dobSPET 1.45, respectively (Figure 2). 
 
Figure 2. Estimated cost for dobutamine stress echocardiography (dobECHO), dobutamine stress SPET 
(dobSPET) and coronary angiography (CA) normalized for cost of exercise ECG = 1. 
 
Analysis of the added cost of different treatment strategies (Table 3), revealed that the cost of 
false positive exams leading to unnecessary coronary angiographies were lowest for 
dobECHO and highest for dobSPET combined with wall motion analysis. The additional 
direct cost of a coronary angiography-only based strategy is NOK 34873 when compared to 
dobECHO with resting wall motion analysis, but actually less costly than any of the dobSPET 
based strategies.   
The average radiation exposure for the patients is 6.0 mSv for coronary angiography and 7.2 
mSv for SPET (Department of Radiation Physics, Oslo University Hospital: personal 














Table 3. Added cost of different diagnostic strategies.  
 CA dobECHO dobECHO + 
WMA 
dobSPET dobSPET + 
WMA 
exECG 
N =  50 50 58 48 48 33 
Cost per exam 
(NOK) 
3356 1961 1961 4867 5867* 829 
No. false 
negatives 
0 6 2 5 0 8 
No. false 
positives 
0 3 19 8 23 2 
Added cost per 
exam** 
NA 201 1275 559 1608 203 
Added cost per 
identified CAD 
by a CA 
strategy*** 
NA 11264 34873 -14522 - ∞ 10444 
WMA = wall motion analysis by echocardiography; CA = coronary angiography; * Added cost of baseline 
echocardiography: 1000. **Cost added due to false positive exam leading to an (unnecessary) coronary 
angiography. CAD = Coronary stenosis. *** calculated as difference in cost between CA and method divided by 




4.1 Focus of an alternative test 
In heart transplant patients, coronary angiography is used as part of the annual follow-up. The 
reason is that coronary artery disease is prevalent and do not elicit typical symptoms in the 
patients due to the denervated transplanted heart. Due to the risks of adverse events as well as 
the cost of coronary angiography, alternatives have been sought for.  The most important 
aspect of the annual follow-up exams is to identify patients who have developed significant 
coronary artery disease. Thus, a test which is positive for myocardial ischemia would lead to 
referral of the patient to coronary angiography. A negative test would decline further 
investigation until next follow-up. A false positive test result implies that a patient without 
coronary artery disease would undergo a coronary angiography which was not needed. A false 
negative result implies that a patient with a significant coronary artery disease would 
(incorrectly) be classified as healthy and further investigation postponed to next follow-up.  
Such a patient carries the risk of acute and chronic myocardial ischemia which relates to 
infarctions, rhythm disturbances, heart failure and sudden death (38).  The latter prospect is by 
far more threatening to the patient than the former. Thus, the focus of any alternative test 
competing coronary angiography should be to minimize the number of false negative exams. 
The present analysis revealed that the diagnostic accuracy of dobECHO and dobSPET 
was comparable, and by far exceeded that of exECG. Moreover, when combining knowledge 
of left ventricular wall motion abnormalities on resting echocardiography with the results of 
stress tests, the number of false negative stress test was reduced from 6 and 5 for dobECHO 
and dobSPET, to 1 and 0, respectively. Whereas, left ventricular wall motion abnormalities 
are evaluated by echocardiography as part of dobECHO, the use of dobSPET would require 
an added resting echocardiography to get access to this information. Moreover, the cost and 
radiation exposure related to dobSPET does hamper its use in a clinical setting where 
dobECHO is available.  
4.2 Coronary artery stenosis versus myocardial ischemia  
There is a principal diagnostic difference between coronary angiography and the alternative 
tests used in the present paper.  Coronary angiography by means of intracoronary injection of 
24 
 
radio-opaque contrast medium displays the coronary arterial anatomy and identifies coronary 
arterial luminal shape and direction. A stenosis of a coronary vessel is identified by a 
reduction of luminal diameter as compared to the preceding vessel segment, and is defined as 
at least 50% diameter reduction. This type of stenosis elicits myocardial ischemia during 
exercise, and do represent an indication for treatment by either percutaneous intervention 
(balloon arterioplasty) or surgery (coronary artery bypass grafting). DobSPET, dobECHO and 
exECG are all methods designed to identify myocardial ischemia. With these methods, 
myocardial ischemia can be identified either as reduced blood flow (perfusion) in the 
ischemic region of the working left ventricular muscular wall by SPET, as reduced thickening 
and movement of the myocardial wall during stress (echocardiography), or as changes in the 
electrical depolarization patterns of the heart (electrocardiogram). Thus, whereas coronary 
angiography identifies vessel anatomy, the other tests are designed to detect the likely 
consequence of significant coronary vessel disease, namely myocardial ischaemia.  
4.3 Discrepancies between diagnostic methods 
From this, it is understandable that the inherent differences between the methods will produce 
discrepant results in some patients. For example, it may be that a particular coronary stenosis 
which was defined significant on coronary angiography, do in fact not elicit myocardial 
ischemia during exercise, for example due to the exercise work load being too low. The 
classification of coronary stenosis on angiograms is also susceptible to variations in 
interpretation, and borderline significant stenosis, i.e. diameter reduction 30-50%, may be 
misclassified. A coronary stenosis misclassified as significant on angiography, with negative 
tests on myocardial ischemia by dobECHO, dobSPET, and exECG would lead to 
misclassification of these tests as false negatives. Other well-known obstacles to interpretation 
of the alternative tests are suboptimal increase in heart rate (dobECHO and dobSPET), 
submaximal exercise work load (exECG), reduced image quality and bundle branch blocks 
(dobECHO and to a lesser degree, dobSPET), suboptimal voltage recordings and bundle 
branch blocks (exECG). 
4.4 Cost analysis 
The high cost of coronary angiography is often used as an argument against its use. In the 
present analysis, coronary angiography was found surprisingly inexpensive with estimated 
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direct costs only 1.7 times cost of dobECHO and in fact less expensive than dobSPET. Thus, 
it is reasonable to maintain that direct costs are not a significant argument against the use of 
coronary angiography.  
The cost of the treatment strategies (Table 2) was lowest for dobECHO and highest for 
dobSPET combined with echocardiographic wall motion analysis. This argument is based on 
the cost of false positives which increase in number with the latter strategy. A false positive 
exam will lead to an unnecessary coronary angiography. On the other hand, it is difficult to 
estimate the cost of false negatives, since exact rates of coronary events linked by different 
sets of coronary vasculopathy is not known in this population. It is, however, known that 
intervention on significant stenosis is a sound clinical strategy (38), thus the strategy which 
reduces the number of false negatives would be preferable.  In this perspective, dobECHO 
with wall motion analysis would be the preferred strategy, but carries an extra cost due to the 
12% rate of false negatives. The estimated additional costs for using a coronary angiography 
based-only strategy was estimated to NOK 34.873 for each false negative dobECHO 
combined with resting wall motion analysis. 
However, one should consider the indirect costs of the methods as well. The rate of significant 
adverse events (acute and chronic) are negligible for dobECHO (i.e. < 10.000)  (39), and 
exECG (28). DobEcho has also been found safe and feasible in the subpopulation of heart 
transplant patients (40). The rate of acute adverse events are low for dobSPET (41), whereas 
coronary angiography has a documented rate of major adverse events of approx. 0.5% (17), 
concordant with the registered rate of major complications (i.e. cerebral emboli, myocardial 
infarction, or pericardial tamponade) at our institution of 0.2% (Quality register, Department 
of Cardiology, Oslo University Hospital, 2011).  
4.5 Radiation exposure 
The long term effects of radiation exposure to the patient and risk for cancer have obtained 
much recent attention (42-45).  The per-capita effective radiation dose of the US population 
from all sources increased by 72% from 1980 to 2006, primarily due to a 5.7 fold increase in 
medical imaging (45). Recently, UK estimates of 700 cancers per year as a cause of medical 
diagnostic imaging with radiation exposure have been presented (46). However, the link 
between radiation effects on living tissue and subsequent cancer development in patients are 
based on wide approximations, in part based on data derived after nuclear bomb detonations 
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in Japan in 1945 (46), and this potential link is under debate (45, 47, 48). The intrinsic risk of 
cancer is much greater than the potential risk of radiation which would be expected to raise 
the relative risk less than 1% (45).  
This said there is general agreement about the “do not harm” principle in medicine which 
infers that medical imaging radiation exposure indeed should be kept as low as possible.  
Coronary angiography and dobSPET both carries a radiation exposure of about 6-7 mSv, 
which is considered moderate (12).  An estimated increase in risk for development of cancer 
for 50 year old persons in the lifetime perspective would be 1 per 1000 tests (0.1%) at this 
level of radiation exposure (49).  When considering the present algorithm of annual follow up 
of the HTx patients, this perspective emerges more important. The median survival of HTX 
patients in Norway is approximately 12 years, and many patients live more than 20 years after 
HTx (19). Considering that cancer development is one of the major threats for these patients 
(19), due to their obligatory immunosuppressive treatment, radiation exposure should 
certainly be kept at a minimum. 
The additional cost of radiation exposure to the personnel is also relevant, but will be but little 
affected by the choice of diagnostic algorithm due to the relatively small population of heart 
transplant patients. 
4.6 Proposed algorithm 
Considering the chronic progressive inflammatory nature of the HTx vasculopathy and the 
inherent inaccuracies of all noninvasive tests, coronary angiography is still needed for 
accurate monitoring of coronary artery status. The question is whether coronary angiograms 
can be intermittently deferred. By choosing dobECHO combined with echocardiographic 
analysis of resting left ventricular wall motion, only 4% false negative tests would be 
expected. The predictive value of a negative dobECHO for subsequent coronary events in 
patients with ischemic heart disease and in HTx population is high (50-52). Thus, it seems 
appropriate to defer coronary angiography at least every second annual follow-up, when 





Advanced cardiac imaging methods for coronary artery disease in heart transplant patients 
carry different precision and cost. ExECG, in spite of being inexpensive, cannot be 
recommended due to its low sensitivity for disease. The diagnostic accuracy of dobECHO and 
dobSPET are comparable, however, the direct cost of dobSPET exceeds dobECHO with a 
factor of 2.5. Moreover, dobSPET carries a significant radiation dose which may contribute to 
the patient’s long-term risk for cancer.  The gold standard, coronary angiography, was less 
expensive than reported elsewhere, but carries a defined risk for acute and long-term adverse 
events. Based on an analysis of cost of the diagnostic tests, dobECHO with wall motion 
analysis is recommended to replace coronary angiography at least every second year in the 
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Background: Coronary vasculopathy is prevalent in heart transplant (HTx) patients, and is a 
major cause of post-transplant morbidity and mortality.  Present follow-up strategies include 
annual coronary angiography which is expensive and carries a risk for the patient. Thus, non-
invasive less costly and low-risk techniques to assess ischemic heart disease in these patients 
are desired.  We tested the diagnostic accuracy and cost of stress echocardiography, stress 
scintigraphy, and exercise ECG to detect coronary stenosis (CAD) in HTx patients. 
Methods:  Fifty stable HTx patients aged (mean±SD) 57±8 years were studied during an 
annual routine control with dobutamine stress echocardiography (dobECHO), dobutamine 
99m
Tc-tetrofosmin emission tomography (dobSPET) and exercise ECG (exECG), and 
compared to the routine coronary angiography.    
Results: Significant coronary artery stenosis in ≥1 major epicardial vessel was present in 14 
patients (28.0%), but only 16 (32.0%) had complete normal angiograms.  Sensitivity, 
specificity and accuracy for CAD as compared to angiograms, was for dobECHO: 67%, 91%, 
and 82%; for dobSPET: 71%, 74%, and 73%; and for exECG: 20%, 91%, and 70%, 
respectively. There were 6 false negatives (12.0%) in dobECHO, 5 (10,4%) in dobSPET, and 
8 (24,2%) in exECG.  By combining dobECHO and dobSPET with resting wall motion data 
on echocardiography, the number of false negatives was reduced to 1 and 0 patients, 
respectively.  Cost of dobECHO, dobSPET and exECG was estimated to 0.58, 1.45, and 0.25 
times the cost of angiography. 
Conclusion: DobECHO and dobSPET are feasible tests in HTx patients.  DobECHO or 
dobSPET combined with echocardiographic resting wall motion analysis, can be used with 
acceptable accuracy for identifying HTx patients in whom routine coronary angiography 
intermittently can be deferred. Of these, dobECHO is the least expensive and carries the least 





Health care expenses have increased significantly in the developed countries over the last 
decades (1). The increasing use of advanced imaging techniques importantly contributes to 
this (2, 3). Moreover, many imaging techniques are based on ionizing radiation, which in the 
long term contributes to risk of cancer (4). Thus, less costly diagnostic techniques with 
minimal hazard, but with adequate accuracy have been sought for. In selected patient 
populations, follow-up care comprises regular investigation with coronary angiography which 
is an invasive and costly procedure with a risk for major adverse events of 0.5% (5). A typical 
example is heart transplant (HTx) patients who conventionally undergo annual coronary 
angiography during follow-up.   
Coronary vasculopathy is prevalent in heart transplant (HTx) patients (6, 7), and 
represents the major limitation for their long-term survival (8). The vasculopathy in HTx 
recipients is characterized by diffuse intimal thickening (9) combined with atheromatous 
lesions, ectasies, stenoses, and distal obliterative disease (7, 10). Treatment of a significant 
coronary artery stenosis in HTx improves patients’ outcome (11).  Due to cardiac denervation, 
these patients usually do not experience typical symptoms as anginal pain, and most follow-
up programmes therefore comprise regular coronary angiography.  Since angiography is 
potentially harmful to the patients (5), costly, and does not always identify the vasculopathy 
correctly (10, 12), accurate noninvasive stress tests have been sought for.   
 Stress echocardiography with dobutamine is a feasible and accurate noninvasive test  
in patients with ischemic heart disease (13-15), but the diagnostic value in HTx patients have 
varied (16-21), although its prognostic value has been proven (22).  Stress perfusion imaging 
and exercise electrocardiograms (ECG) have both demonstrated suboptimal sensitivities for 
significant coronary artery disease in HTx patients (23-25), but have been useful in predicting 
long-term survival (26).  Recently, 
99m
Tc-tetrofosmin has held promise as a more suitable 
agent for diagnosis of allograft vasculopathy (27), and diagnostic accuracy was found to 
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improve when results of stress perfusion testing were combined with resting 
echocardiography data (28). 
 The aim of the present study was to assess prospectively, the diagnostic accuracy and 
cost-effectiveness of dobutamine stress echocardiography (dobECHO), dobutamine stress 
99m
Tc-tetrofosmin perfusion tomography (dobSPET), and ergometer bicycle maximal 
symptom limited exercise ECG testing (exECG) for CAD as compared to the “gold standard” 
coronary angiography, in HTx patients. 
 
PATIENTS AND METHODS 
All heart transplantations and main follow-up of  HTx patients in Norway are performed at 
our institution.  During the time of study, immunosuppressive treatment was a combination of 
cyclosporine A, azathioprine, and prednisolone.  Patients were included after giving writ en 
informed consent. All patients were required to be clinically and hemodynamically stable 
without evidence for transplant rejection on endomyocardial biopsy.  Patients with coronary 
vasculopathy on angiography were selected into the study by an outside observer in order to 
obtain at least 20% of the group with CAD.  Observers were blinded for the coronary status of 
the patients. The purpose of this selection was to assure that the accuracy of the diagnostic 
tests could be evaluated. The study protocol was approved by the Regional Committee for 
Ethics in Medicine.    
 In all, fifty patients were included, and underwent dobECHO, dobSPET, and exECG 
testing less than 4 weeks apart from the cardiac catheterizations with coronary angiography.  
The noninvasive tests were performed after patients had discontinued beta-blockers, calcium 
antagonists, and nitrates for at least 24 hours and in case of long-acting beta-blockers for at 
least 36 hours.  At the day of dobSPET, the patients also abstained from caffeine, tea, and 




Cardiac catheterization: Left heart catheterization with coronary angiography was 
performed by conventional Judkin´s technique and each coronary artery assessed in at least 3 
views.  Coronary vasculopathy was assessed by an experienced radiologist without 
knowledge of patient data.  Each major coronary artery vessel with branches was described, 
i.e. left main stem; left anterior descending artery (LAD) with branches (1. and 2. diagonal 
arteries); circumflex artery (CX) with branches (obtuse marginal, posteriolateral and 
posteriomedial arteries); and right coronary main stem artery (RCA) with branches (right 
descending posterior and atrioventricular branch) in terms of normal, stenotic, or comprising 
diffuse changes in large and/or small coronary arteries or ectasies.  A hemodynamically 
significant stenosis was considered present when diameter stenosis was ≥50%. Diffuse 
changes and ectasies were classified as mild, moderate or severe. In occluded vessels, the 
collateral circulation was also described.   
  Right heart cardiac catheterization was performed using a standard Swan-Ganz 
balloon catheter technique. 
 
Dobutamine stress echocardiography: The stress test was performed with the patient in left 
lateral position.  After resting recordings, dobutamine was infused intravenously in 3-minute 
increments from 5 to 40 µg/kg/min in increments of 3 minutes.  Ultrasound digital images 
from 3 apical and 2 parasternal views were obtained (CFM 750, GE Vingmed Sound, Horten, 
Norway) at baseline, at dobutamine 10 and 20 µg/kg/min and at peak stress.  The images were 
transferred as cineloops to a computer (Macintosh PowerMac, Apple Computers, Cupertino, 
California) for subsequent analysis (29).  We have previously demonstrated the improved 
accuracy by use of this approach (30).  Dobutamine test was not started if systolic or diastolic 
blood pressures were above 200 or 110 mmHg. The test was completed at peak stress defined 
as the occurrence of either 1) new or worsened wall motion abnormality; 2) heart rate ≥85% 
of age determined maximum (220 - age in years); 3) severe hypertension with either systolic 
or diastolic blood pressure above 200 and 110 mmHg, respectively; 4) significant patient 
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discomfort, or 5) peak dobutamine dose (40 µg/kg/min). Brachial artery blood pressures were 
obtained every minute (Dinamap 1846 SXP, Critikon inc., Tampa, FL), and 12 channel 
electrocardiograms every 3 minutes during test.    
 Image analysis was performed off-line by comparing wall motion and thickening in 16 
left ventricular segments at baseline and during test by an experienced observer blinded for 
patient data.  A score was assigned to each of 16 left ventricular segments excluding the 
apical cap (31, 32), where normal wall motion and thickening scored 1, hypokinesia 2, 
akinesia 3, dyskinesia 4, and aneurysm 5.  Intermediate scores, i.e. 1.5, 2.5, and 3.5, were 
allowed to better define the severity of wall motion abnormality.  Resting wall motion 
abnormality was defined as a score ≥2 in ≥1 segment at baseline.  Reversible myocardial 
ischemia was defined as new or progressing wall motion abnormality during test in ≥1 
segment. Irreversible injury was defined as segments with a baseline score ≥2 without 
improvement during test.   
 The analysis was repeated by a blinded second observer for assessment of inter-observer 
repeatability.   
 
Dobutamine stress SPET (99mTechnetium-tetrofosmin myocardial perfusion imaging): 
Baseline perfusion registrations were first obtained. After an overnight fast, 250 MBq 99m 
Technetium-tetrofosmin (Myoview
TM 
, Amersham, Buckinghamshire, UK) were 
intravenously administrated to patients with bodyweight below 75 kg, else 300 MBq was 
given. Single photon emission tomography (SPET) was performed 1 hour later using a dual-




, Elscint, Haifa, Israel). Thirty 
projections of 25 s were acquired over 180
O 
, extending from 45
O
 right anterior oblique to 45
O
 
left posterior oblique in step-and-shoot mode. Later the same day, patients underwent a 
dobutamine stress test protocol identical with that used for the stress echocardiography tests. 
At 1.5 minute at peak dobutamine dose, the infusion was briefly terminated and a second dose 
of 750 MBq (<75 kg) or 900 MBq (≥75 kg) was injected intravenously, before the 
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dobutamine infusion was resumed for the final minute. Following 30 - 60 minutes after test 
termination, a second SPET was performed. 
 Image processing and analysis was performed on the APEX Expert System (Elscint) with 
the CEqual
TM
 software to produce short-axis, vertical and horizontal long-axis tomographic 
slices, bull´s eye plot and 3D images of the left ventricle. The CEqual
TM
 software quantifies 
rest and dobutamine stress distribution of the radionuclide for the short-axis myocardial 
tomograms, and compares the count distribution values to those observed in a normal group 
of patients. Quantification was made for the total myocardium as well as the individual 
vascular regions. In addition to the CEqual
TM
 analysis, an experienced observer unaware of 
the results of the other noninvasive tests and cardiac catherization performed a visual reading 
from the computer screen. Whenever quantification and qualitative analysis were discordant, 
the qualitative visual reading was given priority. 
 
Exercise ECG test: Maximal symptom-limited (general or leg fatigue, shortness of breath or 
lightheadedness) exercise testing was performed using an electrically braked bicycle 
ergometer. The test protocol was individualized using a starting load of 20-50W increasing by 
20-50W every second minute until exhaustion (defined as an inability to keep pedaling rate at 
steady 60 rpm). Simultaneous gas exchange and hemodynamic monitoring were performed. 
Ventilatory oxygen uptake (VO2) was measured using the EOS/SPRINT system (E. Jaeger, 
GmbH CoKG, Wurtzburg, Germany). Gas exchange data were measured with a mixing 
chamber and recorded every 30 s. Oxygen uptake, carbon dioxide output (VCO2), minute 
ventilation (VE), and respiratory exchange ratio (RER) were calculated on-line. Peak oxygen 
uptake (peak VO2) was defined as the highest VO2 achieved during exercise. Age-predicted 
maximal oxygen uptake was calculated according to the equation of Wassermann (33).  Heart 
rate was recorded continuously from an ECG and blood pressure recorded before, during 
exercise, and throughout the recovery period. Subjective perception of fatigue (Borg 6-20 
scale) was recorded throughout exercise. Exercise test was terminated at either of: patient 
42 
 
exhaustion, typical chest pain, significant ST segment depression (≥ 2 mm measured 0.8 s 
after J-point), significant arrhythmias, or hypotension (drop in systolic blood pressure >20 
mmHg).  A test positive for ischemia was defined by a typical change in 2 or more 
electrocardiogram leads with ST segment depression above 1 mm as measured 0.8 s after J-
point on the QRS complex and or major changes in the T-wave vector. Right bundle branch 
block with typical rSR pattern in V1 was defined as complete when QRS duration was at least 
0,12 s, else defined incomplete. 
 
Cost-analysis: The variable and basic cost for each of the four diagnostic methods was 
estimated on the basis of accountancy data from Oslo University Hospital. In addition, the 
following assumptions were made: 1. Personnel cost including overhead was for physician set 
to 1000 NOK per hour, and for technician 500 NOK per hour; 2. Equipment cost, estimated 
equipment lifetime, maintenance cost, and average number of exams per equipment per 
working day were obtained from in-house information; 3. Cost of single-use equipment and 
medication were derived from hospital accountancy; 4. Housing costs were assumed equal for 
the methods. The additional cost by a coronary angiography-only based strategy per false 
negative exam by any other method was obtained as cost of coronary angiography minus cost 
of method divided by %false negative exams (34) 
Statistical analysis: Results are presented as mean values with standard deviation (SD).  The 
results of the respective noninvasive tests were compared to coronary angiography, with 
respect to overall test positivity for ischemia and for the location of ischemia related to the 
typical coronary vessel distribution (Figure 1). In this comparison, coronary stenosis was 
defined significant when ≥ 1 significant stenosis was present in any of the major epicardial 
vessels (LAD, CX or RCA), or in any of their major branches.  Sensitivity, specificity, 
positive and negative predictive values, and diagnostic accuracy of each test were determined 
by conventional methods (35).  Inter-observer agreement for stress echocardiography 




RESULTS   
General characteristics of the patients are given in Table 1.  One patient was excluded from 
stress SPET because of severe hypertension, and for one patient the stress SPET data were 
lost because of technical problems.    
All patients were in sinus rhythm, 16 with normal ECG, 10 with complete and 17 with 
incomplete right bundle branch blocks, 5 had evidence for old anterior myocardial infarction, 
and 2 for left ventricular hypertrophy. None had left bundle branch block. Calcium channel 
antagonists were used by 17 patients, ACE inhibitors by 22, furosemide by 12, alpha-
adrenergic receptor blockers by 5 and beta-adrenergic receptor blockers by 3 patients.  
 
Cardiac catheterization (Table 2): Left ventricular systolic function was generally well 
preserved with normal average values for ejection fraction and end-diastolic pressure.  Only 
one patient had reduced ejection fraction (< 50%), and two had severely elevated filling 
pressures (end-diastolic pressures >20 mmHg).   In all, 18 patients (36.0%) had significant 
stenosis on ≥ 1 of the three major epicardial vessels, 23 (46.0%) had diffuse changes in major 
vessels and 16 (32.0%) in peripheral vessels, 28 (56.0%) had signs of ectatic vessels, 3 (6.0%) 
had fistulas between coronary vessels and right ventricle, and 3 (6.0%) had intracoronary 
stents.  Sixteen patients (32.0%) had completely normal angiograms. Right heart and 
pulmonary artery pressures were normal, and cardiac index was mildly reduced.   
 
Dobutamine stress echocardiography: The dobutamine stress response was adequate (Table 
3), and all but 2 patients reached ≥ 95% of age predicted maximal heart rate, and only 2 
patients received atropine.  None experienced chest pain or showed ischemic ECG changes 
during test.  One patient experienced a brief episode of atrial flutter at high doses of 
dobutamine, and one had a brief sinus arrest, both episodes rapidly normalized after 
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termination of infusion.  Four patients had mild flushing symptoms; else there were no 
adverse reactions during test.   
 Resting wall motion abnormalities in ≥1 segment were present in 37 (74.0%) patients, 17 
(34.0%) in the LAD region exclusively.  Irreversible injury in ≥ 1 segment was present in 17 
(34.0%) patients, 14 (28.0%) in the LAD region.  Overall resting wall motion was moderately 
impaired (Table 3).  Reversible ischemia in ≥1 segment was found in 16 patients (32.0%), 10 
(20.0%) comprising the LAD region.  Sensitivity for significant coronary stenosis was good 
and specificity high (Table 4).  Although specificity for stenoses in the different coronary 
distributions also was high (LAD 85%, CX 98%, and RCA 93%), sensitivity was lower (LAD 
44%, RCA 63%).  Only 3 (6.0%) had stenosis in CX, neither identified with dobECHO.   
 DobECHO identified reversible ischemia in 4 of 6 patients with 2-vessel disease, and in 6 
of 8 with single vessel disease. In the 10 patients with complete right bundle branch blocks, 
dobECHO was correct in 6 and false positive in 4. 
 The inter-observer agreement for interpretation of dobECHO was for reversible ischemia 
in ≥ 1 segment 74%. For the specific coronary distributions, agreement was 72% for ischemia 
in the LAD region, 74% in CX and 72% in the RCA region. The overall agreement for 
irreversible injury, i.e. scar tissue was 84% (80% in the LAD region, 92% in the CX and 88% 
in the RCA).  
 
Dobutamine SPET test: Test response was adequate with average peak heart rate slightly 
above age predicted heart rate maximum (Table 3).  None had chest pain or arrhythmias 
during test.  Except mild flushing symptoms (14 patients) and mild headache (3 patients), 
there were no adverse reactions during test.   
 Resting perfusion abnormalities were found in anterior wall in 10 patients (20.8%) and in 
inferior wall in 7 (14.6%). Evidence for irreversible injury, i.e. fibrosis, was present in 13 
(27.1%) patients, 9 (18.8%) in the LAD region, 2 (4.2%) in the CX region, and 9 (18.8%) in 
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the RCA region, affecting 16±9% of the myocardium. Nineteen patients (39.6%) had 
evidence for reversible ischemia (11-22.9%, in the LAD region), and the ischemic region 
comprised 7±4% of the myocardium.  When reversible ischemia on dobSPET was compared 
to stenosis on angiography, the overall sensitivity and specificity was good (Table 4).  
Specificity for stenosis in the coronary regions was also high (LAD 85%, CX 93%, and RCA 
80%), whereas sensitivity was lower (LAD 63%, RCA 63%).  Only 2 had stenosis in CX, 
neither was identified with dobSPET.   
 DobSPET test identified reversible ischemia in 4 of 5 patients with 2-vessel disease and 
in 5 of 8 with single vessel disease. In the 9 patients with complete right bundle branch blocks 
undergoing dobSPET, the test was correct in 5 and false positive in 4. 
 
Exercise ECG: Test response was considered adequate since all reached anaerobic threshold 
and had subjective rating of fatigue above Borg scale 16. Peak workload was (mean±SD) 
132±39 watts, peak minute oxygen uptake was 17.9±4.3 mL/kg/min, and peak R-value was 
1.15±0.11. Peak heart rate was slightly above age predicted maximum (Table 3) 
 Of 45 patients remitted for exECG, 4 patients (8.9%) could not perform bicycling due to 
physical disabilities and in 8 (17.8%) ECG was not interpretable for ischemic changes due to 
complete right bundle branch block in 7 patients and technically inadequate ECG in one.  
Fifteen patients (33.3%) had incomplete right bundle branch blocks with ECGs found 
adequate for interpretation. Of the 33 patients completing the test, only 4 (12.1%) had ECG 
changes positive for myocardial ischemia, i.e. normalization of inverted T wave during test (1 
patient), deep T wave inversion and mild ST depression during test (2 patients), and typical 
ST depression in the inferior wall leads during test (1 patient).  Whereas specificity was high, 
sensitivity was poor (Table 4).   
 ExECG identified reversible ischemia in none of the 2 patients tested with 2-vessel 




Combining information of the tests (Table 5): By combining information from 
echocardiographic and scintigraphic investigations, sensitivity and negative predictive value 
improved while specificity and positive predictive value decreased. In all, 37 patients (74.0%) 
had resting wall motion abnormalities in ≥1 segment on echocardiography, and 31 (62.0%) 
had abnormalities in ≥ 2 segments. Resting perfusion defects were present in 18 (37.5%) 
patients.  
 By combining resting wall motion abnormalities (≥2 segment) and/or a positive 
dobECHO, false negative tests were limited to 2 patients, with sensitivity 86% and specificity 
47%.  The combination of either resting wall motion abnormalities ≥2 segment on 
echocardiography and/or a positive dobSPET was present in 36 patients (72.0%) comprising 
all those with significant coronary stenosis. All patients with normal resting wall motion and a 
negative dobSPET were free of significant coronary stenosis. There were 23 false positives; 
thus sensitivity was 100% and specificity 34%.  The combination of either resting perfusion 
defects and/or a positive dobSPET was present in 22 patients (45.8%), 3 (6.3%) were false 
negative and 12 (25.0%) false positive, with sensitivity 77% and specificity 66%.  The 
combination of a positive stress echocardiography and/or a positive dobSPET was present in 
25 patients (52.1%); there were 14 (29.2%) false positives and 2 (4.2%) false negatives, with 
specificity 60% and sensitivity 85%.   
 Thus, the combined strategies reduced the number of false negatives and gave high 
negative predictive values, but low positive predictive values.  
 
Cost analysis 
The estimated cost per exam including personnel costs, equipment cost, use of medication and 
single-use equipment was for dobECHO, dobSPET, exECG and coronary angiography NOK 
1.961,  4.867, 829, and 3.356, respectively. Of this cost, the equipment cost per exam was 
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low, i.e. NOK 45, 91, 6, and 57 for the respective methods. Whereas the additional cost by a 
coronary angiography – only based strategy, is NOK 34873 for each false negative dobECHO 
with resting wall motion analysis, this strategy is less expensive (> NOK 14500) than any 
dobSPET based strategy.  
 
DISCUSSION 
HTx vasculopathy represents a diagnostic and therapeutic challenge, since it is often 
asymptomatic and unpredictable in terms of progression rate, severity and clinical 
consequences. Our present follow-up programme includes a coronary angiography where 
percutaneous coronary intervention is the recommended treatment of any significant coronary 
stenosis in a major epicardial artery.  
 The present study demonstrates that both dobECHO and dobSPET are feasible in HTx 
patients, whereas exercise test could only be used in 66% due to resting ECG abnormalities.  
Furthermore, dobECHO and dobSPET had similar and acceptable overall sensitivities for 
coronary artery stenosis, whereas sensitivity of exECG was as low as 22%.  Thus, exECG 
cannot be used in the screening for allograft vasculopathy.   
 The accuracy of the noninvasive tests in the present study was slightly lower than that 
obtained in patients with native ischemic heart disease.  For dobECHO, the overall sensitivity 
was reduced (15, 36, 37), whereas sensitivity for locating the stenoses to the different 
coronary vessels was even lower (27, 38, 39). This may in part be due to the combination of 
resting wall motion, bundle branch blocks, diffuse vasculopathy, and reduced ultrasound 
image quality after thoracotomy in the HTx patients. 
The unique pattern of allograft vasculopathy is likely to be of particular significance since it 
produces diffuse coronary vessel wall affection with peripheral obliterative disease.  It is well 
known that this vasculopathy may not be adequately identified on angiograms (10, 12).  Thus, 
false positive stress tests may be due not only to erroneous interpretation of wall motion or 
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perfusion patterns, but also to significant stenoses that pass undetected on coronary 
angiography. It is also known dobECHO elicit wall motion abnormalities in HTx patients 
without vasculopathy although the mechanism for this is not clear (40).  Similarly, false 
negative stress tests may be caused not only by erroneous stress test interpretation, but also by 
stenosis in a coronary artery producing ischemia in a very small region if any at all, and 
finally to an erroneous interpretation of angiograms due to particular interpretation difficulties 
in these patients. Interestingly, of the 16 patients with completely normal angiograms 14 
(87.5%) had normal dobECHO and dobSPET tests. 
 The particular low accuracy for CX stenosis deserves a comment. Only three patients 
had significant CX stenosis, two with additional stenosis on RCA stenosis and one on LAD. 
In two of these, dobECHO correctly indicated reversible ischemia in the RCA and LAD 
regions, respectively. DobSPET correctly indicated reversible ischemia in RCA region in one 
patient; one did not perform the test. One patient was false negative on both dobECHO and 
dobSPET. Two of the three had false negative exECG and one could not perform the test. 
Whereas the low sensitivity for Cx stenosis is related to the low prevalence, it underscores 
that the stress tests sensitivity for specific coronary vessels is lower than expected, and should 
not be used to predict affected vessel in the individual HTx patient.   
 Bundle branch blocks, particularly right bundle branch block, are prevalent in HTx 
patients. Whereas the accuracy of dobECHO is maintained in patients with left bundle branch 
block (41), that of SPET is reduced, mainly due to reduced specificity (25). However, the 
effects of right bundle branch block on stress tests in HTx patients have not been well 
documented. We found that 20% of the patients had complete and 36% incomplete right 
bundle branch blocks. Complete bundle branch block was associated with false positive tests 
in both dobECHO (4/10) and in dobSPET (4/11) and may in part be explained by the 
associated abnormal sepal movement on echocardiography.  Importantly, none of the patients 
with right bundle branch blocks had false negative stress echocardiography or SPET.  
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 An improved diagnostic accuracy for identification of allograft vasculopathy was 
recently reported by Ciliberto et al., who combined resting wall motion (≥2 segments) on 
echocardiography with results of dipyridamole stress perfusion testing (28). We found that 
sensitivity improved while specificity decreased  by this approach due to the high prevalence 
of resting wall motion abnormalities (n=37) and perfusion defects (n=18).  For instance, of the 
36 patients with either resting wall motion abnormalities ≥ 2 segments and/or positive 
dobSPET, only 13 (36.1%) had significant coronary artery stenosis. Although sensitivity with 
this approach was 100%, specificity was as low as 34% due to the many false positive tests 
(Table 5).  The practical consequence of the combined approach would in our patient group, 
given that the 12/48 patients (25.0%) with normal resting wall motion on echocardiography 
and a negative dobSPET, would be advised to defer their upcoming yearly angiogram. 
Patients with either resting wall motion abnormality and/or a positive dobSPET would be 
advised to have their angiography, and 78% of these would be expected to be without 
significant coronary stenosis.  
 A similar consideration holds for the combination of either resting wall motion 
abnormalities ≥2 segments and/or a positive dobECHO where 19/50 patients would be 
advised to defer angiograms.  Of the 31/50 patients (62.0%) who will be advised annual 
angiogram, 61% would be expected to have normal angiograms. This approach is, however, 
considered more practical in clinical routine since all information is obtained from one 
investigation, i.e. echocardiography, less costly, and does not expose the patient for radiation. 
Although the number of false positives is reduced when combining the results of dobECHO 
with dobSPET, the accuracy was only slightly better.  Dobutamine stress testing is considered 
safe and with minimal patient discomfort (42), the cumulative risk of duplicated repeated 
pharmacological stress testing raise concern, and in our opinion the minor improvement in 





 Dobutamine stress protocol: Dobutamine stress testing in HTx patients is 
considered safe (43), although the chronotropic response is often exaggerated as compared to 
normals (44) and other patient groups (45). This is concordant with our results where all but 
two reached at least 95% of predicted maximal heart rate and only two were given additional 
atropine. The dobutamine test protocol was well tolerated in all patients and atropine is rarely 
needed to achieve predicted maximal heart rate (45).   
 Clinical implications: Both dobECHO and dobSPET had acceptable accuracy for 
significant coronary stenosis in HTx patients; both are feasible and can be used with few side 
effects. Test result in the individual patient should be interpreted as positive vs. negative for 
reversible ischemia without reference to coronary vessel distribution. ExECG cannot be used 
as a diagnostic test for coronary artery disease in these patients. DobECHO is the by far the 
most cost-efficient method. In fact, the cost of dobSPET in fact exceeded that of coronary 
angiography by 45%. DobSPET and coronary angiography exposes the patient for a similar 
level of radiation. Thus, the long term risk of developing radiation-related cancer should be 
similar in dobSPET and coronary angiography, however, the risk of acute complications is in 
principle restricted to the latter method.   
Thus, the present study supports dobECHO and not dobSPET testing as an interim 
supplement for coronary angiography. Although, the cost of coronary angiography is 70% 
above that of dobECHO, the expense per exam is still moderate and probably not high enough 
to argue against annual use in this selected patient group. On the other hand, the calculated 
cost given here is based on plain routine coronary angiograms. Recently, new catheter-based 
techniques e.g. intracoronary pressure measurements and intracoronary ultrasound (IVUS) 
have been increasingly used, and adds to cost.   
Choice of strategy for noninvasive screening for coronary stenosis in these patients depend on 
whether the aim is either to identify all patients with coronary stenoses (higher sensitivity) or 
whether it is to reduce the number of unnecessary coronary angiographies (higher specificity).  
For the first strategy (higher sensitivity), dobECHO should be combined with 
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echocardiographic assessment of resting wall motion abnormalities. A practical clinical 
algorithm (Figure 1) for a patient with normal coronary angiography at last annual follow-up 
would then be to first evaluate resting wall motion on echocardiography. If resting wall 
motion is abnormal, coronary angiography should be adviced.  If resting wall motion is 
normal, the patient progresses to dobECHO. If dobECHO is positive, coronary angiography is 
adviced, if not, angiography is declined.  
For the second strategy (higher specificity), dobECHO alone would be the best option. If test 
result is positive for ischemia, coronary angiography is adviced, if not, it is deferred. 
 
Conclusion: Both dobECHO and dobSPET are feasible and have acceptable accuracy for 
detecting angiographically significant coronary stenosis in HTx patients. ExECG cannot be 
used for this purpose. DobECHO has the lowest cost and represents the least hazard for the 
patient. Depending on strategy for screening for coronary stenosis, dobECHO combined with 
echocardiographic resting wall motion assessment, can with acceptable accuracy help 






1. Smith-Bindman R, Miglioretti DL, Larson EB. Rising use of diagnostic medical 
imaging in a large integrated health system. Health affairs 2008;27:1491-502 
2. Iglehart JK. The new era of medical imaging--progress and pitfalls.N Engl J Med 
2006;354:2822-8 
3. Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM, et al. 
ACCF/ASNC appropriateness criteria for single-photon emission computed tomography 
myocardial perfusion imaging (SPECT MPI). J Am Coll Cardiol 2005;46:1587-605 
4. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates 
for the UK and 14 other countries. Lancet 2004;363:345-51  
5. Werner N, Zahn R, Zeymer U. Stroke in patients undergoing coronary angiography 
and percutaneous coronary intervention: incidence, predictors, outcome and therapeutic 
options. Exp Rev Cardiovasc Ther 2012;10:1297-305 
6. Klauss V, Ackermann K, Spes CH, Zeitlmann T, Henneke KH, Werner F, et al. 
Coronary plaque morphologic characteristics early and late after heart transplantation: in vivo 
analysis with intravascular ultrasonography. Am Heart J 1997;133:29-35  
7. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary 
vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll 
Cardiol 1988;12:334-40 
8. Kaye MP. The Registry of the International Society for Heart and Lung 
Transplantation: tenth official report--1993. The Journal of heart and lung transplantation : the 
official publication of the International Society for Heart Transplantation. 1993;12(4):541-8. 
Epub 1993/07/01. 
9. Rickenbacher PR, Kemna MS, Pinto FJ, Hunt SA, Alderman EL, Schroeder JS, et al. 
Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary 
untrasound study of immunologic and metabolic risk factors. Transplantation 1996;61:46-53 
10. Johnson DE, Alderman EL, Schroeder JS, Gao SZ, Hunt S, DeCampli WM, et al. 
Transplant coronary artery disease: histopathologic correlations with angiographic 
morphology. J Am Coll Cardiol 1991;17:449-57 
11. Syeda B, Roedler S, Schukro C, Yahya N, Zuckermann A, Glogar D. Transplant 
coronary artery disease: Incidence, progression and interventional revascularization. Int J 
Cardiol 2005;104:269-74 
12. Spes CH, Klauss V, Mudra H, Schnaack SD, Tammen AR, Rieber J, et al. Diagnostic 
and prognostic value of serial dobutamine stress echocardiography for noninvasive 
assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and 
intravascular ultrasound. Circulation 1999;100:509-15 
53 
 
13. Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in 
detecting coronary artery disease. Am J Cardiol 1992;69:1269-73  
14. Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography for 
detection and assessment of coronary artery disease. J Am Coll Cardiol 1992;19:1203-11  
15. Marwick T, Willemart B, D'Hondt AM, Baudhuin T, Wijns W, Detry JM, et al. 
Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial 
dysfunction and malperfusion. Comparison of dobutamine and adenosine using 
echocardiography and 99mTc-MIBI single photon emission computed tomography. 
Circulation 1993;87:345-54  
16. Akosah K, Olsovsky M, Mohanty PK. Dobutamine stress-induced angina in patients 
with denervated cardiac transplants. Clinical and angiographic correlates. Chest 
1995;108:695-700  
17. Larsen RL, Applegate PM, Dyar DA, Ribeiro PA, Fritzsche SD, Mulla NF, et al. 
Dobutamine stress echocardiography for assessing coronary artery disease after 
transplantation in children. J Am Coll Cardiol 1998;32:515-20  
18. Derumeaux G, Redonnet M, Mouton-Schleifer D, Bessou JP, Cribier A, Saoudi N, et 
al. Dobutamine stress echocardiography in orthotopic heart transplant recipients. VACOMED 
Research Group. J Am Coll Cardiol 1995;25:1665-72  
19. Herregods MC, Anastassiou I, Van Cleemput J, Bijnens B, De Geest H, Daenen W, et 
al. Dobutamine stress echocardiography after heart transplantation. J Heart Lung Transplant 
1994;13:1039-44  
20. Ciliberto GR, Massa D, Mangiavacchi M, Danzi GB, Pirelli S, Faletra F, et al. High-
dose dipyridamole echocardiography test in coronary artery disease after heart transplantation. 
Eur Heart J 1993;14:48-52  
21. Di Filippo S, Semiond B, Roriz R, Sassolas F, Raboisson MJ, Bozio A. Non-invasive 
detection of coronary artery disease by dobutamine-stress echocardiography in children after 
heart transplantation. J Heart Lung Transplant 2003;22:876-82  
22. Bacal F, Moreira L, Souza G, Rodrigues AC, Fiorelli A, Stolf N, et al. Dobutamine 
stress echocardiography predicts cardiac events or death in asymptomatic patients long-term 
after heart transplantation: 4-year prospective evaluation. J Heart Lung Transplant 
2004;23:1238-44  
23. Legare JF, Haddad H, Barnes D, Sullivan JA, Buth KJ, Hirsch G. Myocardial 
scintigraphy correlates poorly with coronary angiography in the screening of transplant 




24. Smart FW, Ballantyne CM, Cocanougher B, Farmer JA, Sekela ME, Noon GP, et al. 
Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. 
Am J Cardiol 1991;67:243-7  
25. Mairesse GH, Marwick TH, Arnese M, Vanoverschelde JL, Cornel JH, Detry JM, et 
al. Improved identification of coronary artery disease in patients with left bundle branch block 
by use of dobutamine stress echocardiography and comparison with myocardial perfusion 
tomography. Am J Cardiol 1995;76:321-5  
26. Verhoeven PP, Lee FA, Ramahi TM, Franco KL, Mendes de Leon C, Amatruda J, et 
al. Prognostic value of noninvasive testing one year after orthotopic cardiac transplantation. J 
Am Coll Cardiol 1996;28:183-9  
27. Elhendy A, Sozzi FB, van Domburg RT, Vantrimpont P, Valkema R, Krenning EP, et 
al. Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive 
diagnosis of transplant coronary artery stenosis. J Heart Lung Transplant 2000;19:360-6.   
28. Ciliberto GR, Ruffini L, Mangiavacchi M, Parolini M, Sara R, Massa D, et al. Resting 
echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in 
the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis 
after heart transplantation. Eur Heart J 2001;22:964-71  
29. Bjornstad K, Aakhus S, Hatle L. Digital high frame rate stress echocardiography for 
detection of coronary artery stenosis by high dose dipyridamole stress testing. Int J Card Imag 
1995;11:163-70  
30. Bjornstad K, Aakhus S, Hatle L. Comparison of digital dipyridamole stress 
echocardiography and upright bicycle stress echocardiography for identification of coronary 
artery stenosis. Cardiology 1995;86:514-20  
31. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. 
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. 
American Society of Echocardiography Committee on Standards, Subcommittee on 
Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2(5):358-
67 
32. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. 
Standardized myocardial segmentation and nomenclature for tomographic imaging of the 
heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the 
Council on Clinical Cardiology of the American Heart Association. Circulation 
2002;105:539-42  
33. Wasserman K, Hansen JE, Sue DY. Principles of exercise testing and interpretation. 3 
ed. Baltimore: Lippincott, Williams and Wilkins; 1999. 
55 
 
34. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. 
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of 
echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;30:2876-84  
35. Altman DG. Practical statistics for medical research. London: Chapmann and Hall; 
1991. 
36. Cohen JL, Greene TO, Ottenweller J, Binenbaum SZ, Wilchfort SD, Kim CS. 
Dobutamine digital echocardiography for detecting coronary artery disease. Am J Cardiol 
1991;67:1311-8  
37. McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced 
sensitivity for detection of coronary artery disease by addition of atropine to dobutamine 
stress echocardiography. Am J Cardiol 1992;70:41-6  
38. Segar DS, Brown SE, Sawada SG, Ryan T, Feigenbaum H. Dobutamine stress 
echocardiography: correlation with coronary lesion severity as determined by quantitative 
angiography.J Am Coll Cardiol 1992;19:1197-202  
39. Takeuchi M, Araki M, Nakashima Y, Kuroiwa A. Comparison of dobutamine stress 
echocardiography and stress thallium-201 single-photon emission computed tomography for 
detecting coronary artery disease. J Am Soc Echocardiogr 1993;6:593-602  
40. Jackson PA, Akosah KO, Kirchberg DJ, Mohanty PK, Minisi AJ. Relationship 
between dobutamine-induced regional wall motion abnormalities and coronary flow reserve 
in heart transplant patients without angiographic coronary artery disease. J Heart Lung 
Transplant 2002;21:1080-9  
41. Geleijnse ML, Vigna C, Kasprzak JD, Rambaldi R, Salvatori MP, Elhendy A, et al. 
Usefulness and limitations of dobutamine-atropine stress echocardiography for the diagnosis 
of coronary artery disease in patients with left bundle branch block. A multicentre study. Eur 
Heart J 2000;21:1666-73  
42. Mertes H, Sawada SG, Ryan T, Segar DS, Kovacs R, Foltz J, et al. Symptoms, adverse 
effects, and complications associated with dobutamine stress echocardiography. Experience in 
1118 patients. Circulation 1993;88:15-9 
43. Akosah KO, Denlinger B, Mohanty PK. Safety profile and hemodynamic responses to 
beta-adrenergic stimulation by dobutamine in heart transplant patients. Chest 1999;116:1587-
92.   
44. Gerber BL, Bernard X, Melin JA, Delestinne T, Vanbutsele R, Goenen M, et al. 
Exaggerated chronotropic and energetic response to dobutamine after orthotopic cardiac 




45. Flox A, Sanchez V, Delgado JF, Fernandez S, Tello R, Jimenez J, et al. Is atropine 
infusion necessary to achieve the target heart rate in heart transplant patients during 




















Figure 1. Proposed “high sensitivity” algorithm for selection of heart transplantation to 
coronary angiography based on echocardiographic evaluation of left ventricular (LV) wall 
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57 ± 8 
      
 
Time since heart Tx (years) 
 
6,3 ± 3,3 
      
 
Body mass index (kg/m2) 
 
26,4 ± 3,5 
      
 




      
 
Systolic blood pressure (mmHg) 
 
145 ± 21 
      
 
Diastolic blood pressure (mmHg) 
 
93 ± 15 




13,3 ± 1,5 




118 ± 37 
      
 
Cyclosporine A (nmol/L) 
 
124 ± 29 
      
 
 
     
       
  
Table 1.  General patient characteristics. 







      
       
       Left heart catheterization: 
     
       
 
Left ventricular ejection fraction, n=45 (%) 
 
73 ± 12 
 
       
 
Left ventricular end-diastolic pressure (mmHg) 12 ± 5 
 
       
 
Coronary artery diameter stenosis ≥50%* 
 
14 
   
       
 
   1-vessel disease* 
 
8 
   
       
 
   2-vessel disease* 
 
6 
   
       
 
   Patients with LAD stenosis (N)* 
 
9 
   
       
 
   Patients with CX stenosis (N)* 
 
3 
   
       
 
   Patients with RCA stenosis (N)* 
 
8 
   
       Right heart catheterization: 
     
       
 
Pulmonary capillary wedge pressure (mmHg) 
 
9 ± 3 
 
       
 
Mean pulmonary artery pressure (mmHg) 
 
17 ± 4 
 
       
 
Right atrial pressure (mmHg) 
 
5 ± 3 
 
       
 
Cardiac index (L/m2) 
 
2,6 ± 0,6 
 
       
 
Pulmonary arterial resistance (Woods units) 
 




      
       
       
       
        
  
Table 2.  Cardiac catherization data. 
Values are mean±SD or per cent (%). * Number of patients. LAD = Left anterior 




               
 
 
              
               
               
               
               
               
    
dobECHO 
   
dobSPET 
   
ExECG 
  
    
(n=50) 
   
(n=48) 
   
(n=33) 
          
 
                    
 
Peak dose DOB 
(µg/kg/min) 29 ± 9 
 
27 ± 9 
 
- 
   
               
 
BL HR (b/min) 
 
90 ± 13 
 
85 ± 13 
 
103 ± 13 
 
               
 
Peak HR (b/min) 
 
145 ± 8 
 
140 ± 12 
 
150 ± 19 
 
               
 
% increase in HR 
 
64 ± 26 
 
69 ± 27 
 
47 ± 21 
 
               
 
HR in % of max* 
 
105 ± 6 
 
101 ± 8 
 
109 ± 13 
 
               
 
BL SBP (mmHg) 
 
133 ± 27 
 
145 ± 18 
 
128 ± 21 
 
               
 
Peak SBP (mmHg) 
 
131 ± 25 
 
158 ± 23 
 
185 ± 30 
 
               
 
% increase in SBP 
 
0 ± 19 
 
9 ± 16 
 
41 ± 32 
 




19031 ± 3692 
 
22062 ± 3629 
 
28493 ± 6721 
 
               
 
% increase in HRxSBP 
 
66 ± 42 
 
85 ± 42 
 
118 ± 54 
 
               
 
BL WMSI (units) 
 
1,22 ± 0,24 
 
- 
   
- 
   
               
 
Peak WMSI (units) 
 
1,15 ± 0,21 
 
- 
   
- 
   
               
               
  
 
                            
               
               
               
               
                 
Table 3.  Hemodynamic response during stress testing in stable heart transplant patients. 
dobECHO= Dobutamine stress echocardiography; dobSPET=Dobutamine stress Tc SPET; ExECG=Bicycle ergometer 
exercise ECG; HR=Heart rate; SBP=Systolic blood pressure; *max=estimated maximal HR (220-age(years)); BL 






            
             
             
             
             
             
             
   
dobECHO dobSPET exECG 
  
             







             

























             














































             
  
 
                      
 
             
             
               
Table 4.  Detection of coronary artery stenosis (CAD) by noninvasive stress 
tests in stable heart transplant patients. 
Boxes comprise numbers of patients. CAD: significant stenosis on coronary angiography of 
≥50% diameter stenosis in a major coronary artery or any of its major branches. Abbrev. as 






               
                
                
                
                
                
   
WMA BL echo    WMA BL echo    SPET BL abn  dobECHO   
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Table 5.  Effect on diagnostic accuracy of detection of coronary artery stenosis (CAD) in 
stable heart transplant patients by combining information from the noninvasive tests. 
Boxes comprise numbers of patients. CAD: significant stenosis on coronary angiography of ≥50% diameter stenosis in a 
major coronary artery or any of its major branches. WMA BL echo: Wall motion abnormality on resting echocardiography ≥ 
2 segments; SPET BL abn: perfusion abnormalities on resting SPET. Other abbrev. as in Table 3.  
